prikaz prve stranice dokumenta Comprehensive molecular and clinical insights into non-small cell lung cancer transformation to small cell lung cancer with an illustrative case report
  Preuzmi
PDF 4.3 MB
Znanstveni rad - Pregledni rad
Comprehensive molecular and clinical insights into non-small cell lung cancer transformation to small cell lung cancer with an illustrative case report
Journal of Drug Targeting, x (2024), x; 1-11. https://doi.org/10.1080/1061186X.2024.2332733
Tomić, Krešimir; Krpina, Kristina; Batičić, Lara; Samaržija, Miroslav; Vranić, Semir

Institucijski repozitorij: Repozitorij Medicinskog fakulteta u Rijeci

Citirajte ovaj rad

Tomić, K., Krpina, K., Batičić, L., Samaržija, M. i Vranić, S. (2024). Comprehensive molecular and clinical insights into non-small cell lung cancer transformation to small cell lung cancer with an illustrative case report. Journal of Drug Targeting, x. (x), 1-11. doi: 10.1080/1061186X.2024.2332733

Tomić, Krešimir, et al. "Comprehensive molecular and clinical insights into non-small cell lung cancer transformation to small cell lung cancer with an illustrative case report." Journal of Drug Targeting, vol. x, br. x, 2024, str. 1-11. https://doi.org/10.1080/1061186X.2024.2332733

Tomić, Krešimir, Kristina Krpina, Lara Batičić, Miroslav Samaržija i Semir Vranić. "Comprehensive molecular and clinical insights into non-small cell lung cancer transformation to small cell lung cancer with an illustrative case report." Journal of Drug Targeting x, br. x (2024): 1-11. https://doi.org/10.1080/1061186X.2024.2332733

Tomić, K., et al. (2024) 'Comprehensive molecular and clinical insights into non-small cell lung cancer transformation to small cell lung cancer with an illustrative case report', Journal of Drug Targeting, x(x), str. 1-11. doi: 10.1080/1061186X.2024.2332733

Tomić K, Krpina K, Batičić L, Samaržija M, Vranić S. Comprehensive molecular and clinical insights into non-small cell lung cancer transformation to small cell lung cancer with an illustrative case report. Journal of Drug Targeting [Internet]. 25.03.2024. [pristupljeno 21.05.2024.];x(x):1-11. doi: 10.1080/1061186X.2024.2332733

K. Tomić, K. Krpina, L. Batičić, M. Samaržija i S. Vranić, "Comprehensive molecular and clinical insights into non-small cell lung cancer transformation to small cell lung cancer with an illustrative case report", Journal of Drug Targeting, vol. x, br. x, str. 1-11, Ožujak 2024. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:634605. [Citirano: 21.05.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:634605
Podaci o radu
Naslov (engleski)Comprehensive molecular and clinical insights into non-small cell lung cancer transformation to small cell lung cancer with an illustrative case report
AutorKrešimir Tomić
AutorKristina Krpina
AutorLara Batičić
AutorMiroslav Samaržija
AutorSemir Vranić
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za medicinsku kemiju, biokemiju i kliničku kemiju)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Onkologija
Sažetak (engleski)
Histologic transformation to small cell lung cancer (tSCLC) is a rare but increasingly recognised mechanism of acquired resistance to tyrosine kinase inhibitors (TKI) in patients with epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer (NSCLC). Beyond its acknowledged role in TKI resistance, histologic transformation to SCLC might be an important, yet under-recognised, mechanism of resistance in NSCLC treated with immunotherapy. Our review identified 32 studies that investigated tSCLC development in patients with EGFR-mutated NSCLC treated with TKI therapy and 16 case reports of patients treated with immunotherapy. It revealed the rarity of tSCLC, with a predominance of EGFR exon 19 mutations and limited therapeutic options and outcomes. Across all analysed studies in EGFR-mutated NSCLC treated with TKI therapy, the median time to tSCLC development was similar to 17 months, with a median overall survival of 10 months. Histologic transformation of EGFR-mutated NSCLC to SCLC is a rare, but challenging clinical problem with a poor prognosis. A small number of documented cases of tSCLC after immunotherapy highlight the need for rebiopsies at progression to diagnose this potential resistance mechanism. Further research is needed to better understand the mechanisms underlying this phenomenon and to develop more effective treatment strategies for patients with tSCLC.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Pregledni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaJournal of Drug Targeting
Brojčani podacivol. x, br. x, str. 1-11
p-ISSN1061-186X
e-ISSN1029-2330
DOIhttps://doi.org/10.1080/1061186X.2024.2332733
URN:NBNurn:nbn:hr:184:634605
Datum objave publikacije2024-03-25
URL dokumentahttps://www.tandfonline.com/doi/full/10.1080/1061186X.2024.2332733
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje-Nekomercijalno 4.0 međunarodna (CC BY-NC 4.0)
Datum i vrijeme pohrane2024-04-29 09:04:27